Overall, these data suggest that anti-ST2-neutralizing antibodies limit the progression of aggressive leukemia and rescue it at a lower burden of leukemia by protecting CD8 T cells from cytolysis by ST2+ Treg cells in both immunocompetent and humanized pre-clinical models. The gene discussed is CD8A; the disease is leukemia.